Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts
- 18 April 2012
- journal article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 14 (3), 445-455
- https://doi.org/10.1208/s12248-012-9357-2
Abstract
To date, there has been little investigation of the risk for drug–drug interactions involving monoclonal antibodies. The present work examined the effects of an anti-vascular endothelial growth factor (anti-VEGF) antibody on the plasma, tissue, and tumor disposition of T84.66, an anti-carcinoembryonic antigen (CEA) antibody, in mice. SCID mice bearing CEA-expressing human colorectal cancer (LS174T) xenografts were divided into control and anti-VEGF-treated groups. When tumors reached 200–300 mm3 in size, 125I-T84.66 was administered intravenously at 10 mg/kg (400 μCi/kg). Radioactivity in plasma and tissue samples was counted, and T84.66 concentrations were determined. Areas under the concentration vs. time curves (AUC) were calculated. In separate groups of mice, Evans Blue Dye was administered to evaluate the effect of anti-VEGF on tumor vascular permeability. The investigations did not demonstrate significant effects of anti-VEGF therapy on T84.66 pharmacokinetics in plasma or in non-tumor tissues. T84.66 plasma AUC(0–10 days) values were 2.37 × 103 ± 1.54 × 102 and 2.56 × 103 ± 1.01 × 102 nM × day, for the control and treated groups (p = 0.148). Conversely, anti-VEGF treatment significantly reduced tumor vascular permeability to Evans Blue Dye by 45.0 % (p = 0.0012), and anti-VEGF therapy decreased T84.66 tumor AUC(0–10 days) by more than 60 % (7.27 × 102 ± 51.4 vs. 1.98 × 103 ± 90.1 nM × day, p < 0.0001). Our findings suggest that anti-VEGF therapies may lead to a substantial reduction in the delivery of monoclonal antibodies to tumor tissues. It is interesting and important to note that this pharmacokinetic interaction occurs at the target site, and that no alterations in T84.66 disposition were visible based on assessment of plasma pharmacokinetics alone.Keywords
This publication has 31 references indexed in Scilit:
- Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood FlowPLOS ONE, 2011
- Mechanisms of Monoclonal Antibody–Drug InteractionsAnnual Review of Pharmacology and Toxicology, 2011
- Bevacizumab improves the delivery and efficacy of paclitaxelAnti-Cancer Drugs, 2010
- CYP-Mediated Therapeutic Protein-Drug InteractionsClinical Pharmacokinetics, 2010
- Drug interactions evaluation: An integrated part of risk assessment of therapeuticsToxicology and Applied Pharmacology, 2010
- Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibodyJournal of Pharmaceutical Sciences, 2010
- Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal ChemotherapyJournal of Pharmacology and Experimental Therapeutics, 2009
- Drug Interaction Studies of Therapeutic Proteins or Monoclonal AntibodiesThe Journal of Clinical Pharmacology, 2007
- Pharmacokinetic Effects of 4C9, An Anti-FcRn Antibody, in Rats: Implications for the Use of FcRn Inhibitors for the Treatment of Humoral Autoimmune and Alloimmune ConditionsJournal of Pharmaceutical Sciences, 2005
- An extension of satterth waite's approximation applied to pharmacokineticsJournal of Biopharmaceutical Statistics, 1998